NCT00072631View on ClinicalTrials.gov

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 5, 2003

Primary Completion Date

March 14, 2007

Study Completion Date

March 14, 2007

Conditions
Advanced Non Small Cell Lung CancerFailed Prior Chemotherapy
Interventions
DRUG

Tarceva (Trademark) (erlotinib HCl, OSI-774)

Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash

Trial Locations (1)

78229

Institute for Drug Development Cancer Therapy and Research Center, San Antonio

Sponsors
All Listed Sponsors
lead

OSI Pharmaceuticals

INDUSTRY